SCHEMBL384041

SCHEMBL384041

Clc1cccc(C(Br)Br)c1

nearest known ligand 0.46

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
ACP3 P15309 1/20 0.46
ALDH1A1 P00352 1/20 0.42
TSHR P16473 1/20 0.42
AOC3 Q16853 1/20 0.41
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
OPRM1 P35372 4/20 0.39
OPRD1 P41143 4/20 0.39
OPRK1 P41145 4/20 0.39
OPRL1 P41146 4/20 0.39
PNMT P11086 2/20 0.38
CHRM5 P08912 1/20 0.37
SLC6A2 P23975 1/20 0.36
SLC6A4 P31645 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17061793 0.85 ACP3 (0.46) ACP3ALDH1A1TSHRAOC3MEN1
SCHEMBL28258021 0.83 ACP3 (0.44) ACP3ALDH1A1TSHRAOC3MEN1
SCHEMBL11215002 0.82 FNTA (0.41) SLC6A2SLC6A4
SCHEMBL28029483 0.81 ACP3 (0.43) ACP3ALDH1A1TSHRAOC3MEN1
SCHEMBL626360 0.81 PNMT (0.44) ACP3ALDH1A1TSHRAOC3OPRM1
SCHEMBL30057167 0.81 PNMT (0.44) ACP3ALDH1A1TSHRAOC3OPRM1
SCHEMBL27933368 0.81 ACP3 (0.47) ACP3ALDH1A1TSHRAOC3MEN1
SCHEMBL3656714 0.81 ACP3 (0.43) ACP3ALDH1A1TSHRAOC3MEN1
SCHEMBL1410478 0.81 ACP3 (0.43) ACP3ALDH1A1TSHRAOC3MEN1
SCHEMBL903821 0.81 ACP3 (0.43) ACP3ALDH1A1TSHRAOC3MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025224262-A1 COMBINATION THERAPIES COMPRISING A CDK2 DEGRADER AND A CDK4/6 INHIBITOR MONTE ROSA THERAPEUTICS AG (CH) 2025-10-30 WO disclosed
EP-4638436-A1 PRMT5 INHIBITORS AND USES THEREOF GILEAD SCIENCES, INC. (US) 2025-10-29 EP disclosed
WO-2024137852-A1 PRMT5 INHIBITORS AND USES THEREOF GILEAD SCIENCES, INC. (US) 2024-06-27 WO disclosed
EP-4192582-A1 KINASE INHIBITORS AND USES THEREOF ABM Therapeutics Corporation (US) 2023-06-14 EP disclosed
WO-2023069708-A1 COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND USES THEREOF MONTE ROSA THERAPEUTICS, INC. (US) 2023-04-27 WO disclosed
EP-4146644-A1 IL4I1 INHIBITORS AND METHODS OF USE Merck Sharp & Dohme LLC (US) 2023-03-15 EP disclosed
WO-2022032071-A1 KINASE INHIBITORS AND USES THEREOF ABM THERAPEUTICS CORPORATION (US) 2022-02-10 WO disclosed
WO-2021226003-A1 IL4I1 INHIBITORS AND METHODS OF USE MERCK SHARP & DOHME CORP. (US) 2021-11-11 WO disclosed
EP-3898633-A1 SUBSTITUTED OXOPYRIDINE DERIVATIVES Bayer Aktiengesellschaft (DE) 2021-10-27 EP disclosed
CN-107098791-B Preparation method of benzyl bromide 浙江师范大学 2021-01-26 CN disclosed
WO-2006109085-A1 HYDROXYBENZAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF HSP90 ASTEX THERAPEUTICS LIMITED (GB) 2006-10-19 WO disclosed
WO-2006049952-A1 CYCLOALKYL LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 ELI LILLY AND COMPANY (US) 2006-05-11 WO disclosed
EP-1421074-A1 NOVEL COMPOUNDS AstraZeneca AB (SE) 2004-05-26 EP disclosed
WO-2003010158-A1 NOVEL COMPOUNDS ASTRAZENECA AB (SE) 2003-02-06 WO disclosed
US-5698580-A TREATING DISEASES CAUSED BY RESPIRATORY SYNCYTIAL VIRUS RATIONAL DRUG DESIGN LABORATORIES (JP) 1997-12-16 US disclosed
EP-0770609-A1 ANTIVIRAL AGENT CONTAINING BENZODITHIIN DERIVATIVE AS ACTIVE INGREDIENT Rational Drug Design Laboratories (JP) 1997-05-02 EP disclosed
EP-0238753-B1 N-SUBSTITUTED CONDENSED POLYMETHYLENE IMINE DERIVATIVES BEECHAM GROUP PLC (GB) 1992-01-15 EP disclosed
US-4959374-A HYPOTENSIVE AGENTS, ANTICOAGULANTS, GLAUCOMA, HYPERGLYCEMIC AGENTS, ANTIDEPRESSANTS BEECHAM GROUP P.L.C. (GB) 1990-09-25 US disclosed
US-4863946-A HYPOGLYCEMIC AND HYPOTENSIVE AGENTS BEECHAM GROUP PLC (GB) 1989-09-05 US disclosed
EP-0238753-A1 N-substituted condensed polymethylene imine derivatives BEECHAM GROUP PLC (GB) 1987-09-30 EP disclosed